Evaluation of Immunogenicity and Safety of the New Tetanus-Reduced Diphtheria (Td) Vaccines (GC1107) in Healthy Korean Adolescents: A Phase II, Double-Blind, Randomized, Multicenter Clinical Trial.
10.3346/jkms.2013.28.4.586
- Author:
Jung Woo RHIM
1
;
Kyung Yil LEE
;
Sang Yong KIM
;
Jong Hyun KIM
;
Hyun Hee KIM
;
Hwang Min KIM
;
Young Youn CHOI
;
Sang Hyuk MA
;
Dong Ho KIM
;
Dong Ho AHN
;
Jin Han KANG
Author Information
1. Department of Pediatrics, The Catholic University of Korea, Seoul, Korea. kjhan@catholic.ac.kr
- Publication Type:Original Article ; Clinical Trial, Phase II ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Tetanus-Reduced Diphtheria (Td) Vaccine;
Immunogenicity;
Safety
- MeSH:
Antibodies, Bacterial/blood;
Arthralgia/etiology;
Child;
Diphtheria/*prevention & control;
Diphtheria-Tetanus Vaccine/adverse effects/*immunology;
Double-Blind Method;
Female;
Headache/etiology;
Humans;
Male;
Pain/etiology;
Tetanus/*prevention & control;
Treatment Outcome;
Vaccination
- From:Journal of Korean Medical Science
2013;28(4):586-592
- CountryRepublic of Korea
- Language:English
-
Abstract:
This phase II clinical trial was conducted to compare the immunogenicity and safety of a newly developed tetanus-reduced diphtheria (Td) vaccine (GC1107-T5.0 and GC1107-T7.5) and control vaccine. This study was also performed to select the proper dose of tetanus toxoid in the new Td vaccines. Healthy adolescents aged between 11 and 12 yr participated in this study. A total of 130 subjects (44 GC1107-T5.0, 42 GC1107-T7.5 and 44 control vaccine) completed a single dose of vaccination. Blood samples were collected from the subjects before and 4 weeks after the vaccination. In this study, all subjects (100%) in both GC1107-T5.0 and GC1107-T7.5 groups showed seroprotective antibody levels (> or = 0.1 U/mL) against diphtheria or tetanus toxoids. After the vaccination, the geometric mean titer (GMT) against diphtheria was significantly higher in Group GC1107-T5.0 (6.53) and GC1107-T7.5 (6.11) than in the control group (3.96). The GMT against tetanus was 18.6 in Group GC1107-T5.0, 19.94 in GC1107-T7.5 and 19.01 in the control group after the vaccination. In this study, the rates of local adverse reactions were 67.3% and 59.1% in GC1107-T5.0 and GC1107-7.5, respectively. No significant differences in the number of adverse reactions, prevalence and degree of severity of the solicited and unsolicited adverse reactions were observed among the three groups. Thus, both newly developed Td vaccines appear to be safe and show good immunogenicity. GC1107-T5.0, which contains relatively small amounts of tetanus toxoid, has been selected for a phase III clinical trial.
